Catalyst Pharmaceuticals Share Price (NASDAQ: CPRX)

$20.12

▲

0.18

(0.9%)

Live

Last updated on August 28, 2025 at 12:36 am IST

$₹

Check the interactive Catalyst Pharmaceuticals Stock chart to analyse performance

Catalyst Pharmaceuticals stock performance

as on August 28, 2025 at 12:36 am IST

Today's Low:$19.96
Today's High:$20.32
$20.12
0.8%
Downside
Day's Volatility :1.77%
Upside
0.98%
52 Weeks Low:$19.00
52 Weeks High:$26.58
$20.12
5.57%
Downside
52 Weeks Volatility :28.52%
Upside
24.3%

Catalyst Pharmaceuticals Stock Returns

Period	Catalyst Pharmaceuticals Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-18.77%	3.7%	0.0%
6 Months	-3.13%	-6.9%	0.0%
1 Year	-2.61%	-11.9%	0.0%
3 Years	41.18%	7.7%	-6.9%

Catalyst Pharmaceuticals Inc Key Stats

Check Catalyst Pharmaceuticals key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$19.94
Open	$20.73
Today's High	$20.32
Today's Low	$19.96
Market Capitalization	$2.4B
Today's Volume	$1.7M
52 Week High	$26.58
52 Week Low	$19.0
Revenue TTM	$558.5M
EBITDA	$281.2M
Earnings Per Share (EPS)	$1.65
PE Ratio	12.08
Profit Margin	37.36%
Quarterly Earnings Growth YOY	0.24%
Return On Equity TTM	28.49%

Stock Returns calculator for Catalyst Pharmaceuticals Stock including INR - Dollar returns

The Catalyst Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Catalyst Pharmaceuticals investment value today

Current value as on today

₹1,02,963

Returns

₹2,963

(+2.96%)

Returns from Catalyst Pharmaceuticals Stock

₹1,710 (-1.71%)

Dollar Returns*

₹4,673 (+4.67%)

Indian investors sentiment towards Catalyst Pharmaceuticals Stock

Period: Jul 27, 2025 to Aug 26, 2025. Change in 30 Days versus previous period

Search interest for Catalyst Pharmaceuticals Stock from India on INDmoney has increased by 6% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Catalyst Pharmaceuticals Inc

Name
Holdings %
Name
Holdings %
BlackRock Inc
15.36%
Vanguard Group Inc
7.16%
State Street Corp
4.52%
Renaissance Technologies Corp
2.42%
Deerfield Management Co
2.35%
Geode Capital Management, LLC
2.26%

Analyst Recommendation on Catalyst Pharmaceuticals Stock

Rating

Trend

Buy

92%Buy

7%Hold

0%Sell

Based on 13 Wall street analysts offering stock ratings for Catalyst Pharmaceuticals(by analysts ranked 0 to 5 stars)

Catalyst Pharmaceuticals Share Price Target

What analysts predicted

Upside of 70.41%

Target:

$34.29

Current:

$20.12

Catalyst Pharmaceuticals share price target is $34.29, a slight Upside of 70.41% compared to current price of $20.12 as per analysts' prediction.

Catalyst Pharmaceuticals Stock Insights

Price Movement
In the last 7 days, CPRX stock has moved down by -2.0%
Increasing Revenue
Revenue is up for the last 2 quarters, 141.42M → 146.56M (in $), with an average increase of 3.5% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 56.73M → 52.10M (in $), with an average decrease of 8.2% per quarter
CPRX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 61.0% return, outperforming this stock by 63.6%
CPRX vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 113.9% return, outperforming this stock by 71.7%
Price to Sales
ForCPRX every $1 of sales, investors are willing to pay $4.3, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.7 for every $1 of sales.

Catalyst Pharmaceuticals Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$102.3M	↑ 20361.27%
Net Income	$31.9M	↓ 193.74%
Net Profit Margin	31.16%	↑ 6831.86%

	FY20	Y/Y Change
Revenue	$119.1M	↑ 16.39%
Net Income	$75.0M	↑ 135.24%
Net Profit Margin	62.97%	↑ 31.81%

	FY21	Y/Y Change
Revenue	$140.8M	↑ 18.27%
Net Income	$39.5M	↓ 47.35%
Net Profit Margin	28.03%	↓ 34.94%

	FY22	Y/Y Change
Revenue	$214.2M	↑ 52.1%
Net Income	$83.1M	↑ 110.42%
Net Profit Margin	38.79%	↑ 10.76%

	FY23	Y/Y Change
Revenue	$398.2M	↑ 85.9%
Net Income	$71.4M	↓ 14.05%
Net Profit Margin	17.93%	↓ 20.86%

	FY24	Y/Y Change
Revenue	$491.7M	↑ 23.49%
Net Income	$163.9M	↑ 129.5%
Net Profit Margin	33.33%	↑ 15.4%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$98.5M	↓ 10.91%
Net Income	$23.3M	↓ 33.2%
Net Profit Margin	23.63%	↓ 7.88%

	Q2 FY24	Q/Q Change
Revenue	$122.7M	↑ 24.57%
Net Income	$40.8M	↑ 75.27%
Net Profit Margin	33.24%	↑ 9.61%

	Q3 FY24	Q/Q Change
Revenue	$128.7M	↑ 4.88%
Net Income	$43.9M	↑ 7.57%
Net Profit Margin	34.1%	↑ 0.86%

	Q4 FY24	Q/Q Change
Revenue	$141.8M	↑ 10.2%
Net Income	$55.9M	↑ 27.46%
Net Profit Margin	39.44%	↑ 5.34%

	Q1 FY25	Q/Q Change
Revenue	$141.4M	↓ 0.28%
Net Income	$56.7M	↑ 1.43%
Net Profit Margin	40.12%	↑ 0.68%

	Q2 FY25	Q/Q Change
Revenue	$146.6M	↑ 3.64%
Net Income	$52.1M	↓ 8.16%
Net Profit Margin	35.55%	↓ 4.57%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$87.5M	↑ 17409.44%

	FY20	Y/Y Change
Profit	$102.0M	↑ 16.55%

	FY21	Y/Y Change
Profit	$118.9M	↑ 16.58%

	FY22	Y/Y Change
Profit	$179.8M	↑ 51.17%

	FY23	Y/Y Change
Profit	$313.7M	↑ 74.45%

	FY24	Y/Y Change
Profit	$422.9M	↑ 34.82%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$86.0M	↑ 0.34%

	Q2 FY24	Q/Q Change
Profit	$98.0M	↑ 13.92%

	Q3 FY24	Q/Q Change
Profit	$109.4M	↑ 11.7%

	Q4 FY24	Q/Q Change
Profit	$120.2M	↑ 9.83%

	Q1 FY25	Q/Q Change
Profit	$123.5M	↑ 2.77%

	Q2 FY25	Q/Q Change
Profit	$116.6M	↓ 5.59%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$34.6M	↓ 234.65%
Investing Cash Flow	$37.2M	↓ 339.76%
Financing Cash Flow	$1.1M	↑ 280.82%

	FY20	Y/Y Change
Operating Cash Flow	$45.0M	↑ 30.12%
Investing Cash Flow	$-5.0M	↓ 113.46%
Financing Cash Flow	$701.9K	↓ 37.12%

	FY21	Y/Y Change
Operating Cash Flow	$60.4M	↑ 34.06%
Investing Cash Flow	$-11.0M	↑ 119.92%
Financing Cash Flow	$-8.1M	↓ 1260.08%

	FY22	Y/Y Change
Operating Cash Flow	$116.0M	↑ 92.22%
Investing Cash Flow	$9.2M	↓ 183.56%
Financing Cash Flow	$1.7M	↓ 120.8%

	FY23	Y/Y Change
Operating Cash Flow	$143.6M	↑ 23.74%
Investing Cash Flow	$-293.5M	↓ 3287.12%
Financing Cash Flow	$-10.9M	↓ 740.91%

	FY24	Y/Y Change
Operating Cash Flow	$239.8M	↑ 67.0%
Investing Cash Flow	$-556.0K	↓ 99.81%
Financing Cash Flow	$140.7M	↓ 1395.62%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$31.9M	↓ 42.63%
Investing Cash Flow	$-199.0K	↓ 99.48%
Financing Cash Flow	$141.0M	↓ 21310.38%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$64.1M	↑ 100.89%
Investing Cash Flow	$-10.0K	↓ 94.97%
Financing Cash Flow	$1.2M	↓ 99.18%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$72.9M	↑ 13.62%
Investing Cash Flow	$-259.0K	↑ 2490.0%
Financing Cash Flow	$-6.0M	↓ 616.34%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$70.9M	↓ 2.74%
Investing Cash Flow	$-88.0K	↓ 66.02%
Financing Cash Flow	$4.4M	↓ 174.2%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$71.3M	↑ 18.74%
Investing Cash Flow	$-26.0K	-
Financing Cash Flow	$872.0K	↓ 71.5%

Catalyst Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Catalyst Pharmaceuticals is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Catalyst Pharmaceuticals Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Catalyst Pharmaceuticals Inc	-4.16%	-3.13%	-2.61%	41.18%	500.45%
Regeneron Pharmaceuticals, Inc.	5.16%	-16.9%	-51.12%	-0.89%	-2.51%
Beone Medicines Ltd	4.54%	18.87%	52.28%	84.02%	26.72%
Vertex Pharmaceuticals Incorporated	-16.02%	-19.22%	-19.42%	37.43%	43.36%
Alnylam Pharmaceuticals, Inc.	38.9%	84.99%	60.96%	115.82%	243.29%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Catalyst Pharmaceuticals Inc	12.08	12.08	0.0	2.34	0.28	0.18	NA	7.0
Regeneron Pharmaceuticals, Inc.	14.86	14.86	1.21	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.29	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.64	27.64	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Catalyst Pharmaceuticals Inc	Buy	$2.4B	500.45%	12.08	37.36%
Regeneron Pharmaceuticals, Inc.	Buy	$62.5B	-2.51%	14.86	31.37%
Beone Medicines Ltd	NA	$38.3B	26.72%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$99.7B	43.36%	27.64	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$58.2B	243.29%	NA	-12.96%

About Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Organization	Catalyst Pharmaceuticals
Employees	181
CEO	Mr. Richard John Daly M.B.A.
Industry	Health Technology

Key Management of Catalyst Pharmaceuticals Inc

Name	Title
Mr. Richard John Daly M.B.A.	President, CEO & Director
Mr. Michael W. Kalb CPA	Executive VP, Treasurer & CFO
Dr. Steven R. Miller Ph.D.	Executive VP, COO & Chief Scientific Officer
Mr. Jeffrey Del Carmen	Executive VP & Chief Commercial Officer
Dr. Preethi Sundaram Ph.D.	Chief Strategy Officer
Ms. Mary Coleman	VP & Head of Investor Relations
Mr. Brian Elsbernd J.D.	Chief Compliance Officer & Chief Legal Officer
Mr. Gregg Russo	Chief Human Resources Officer
Dr. Stanley Iyadurai M.D., Ph.D.	Senior Vice President of Medical Affairs & Drug Discovery
Dr. William T. Andrews FACP, M.D.	Chief Medical Officer

Important FAQs about investing in CPRX Stock from India :

What is Catalyst Pharmaceuticals share price today?

Catalyst Pharmaceuticals share price today is $20.12 as on August 28, 2025 at 12:36 am IST. Catalyst Pharmaceuticals share today touched a day high of $20.32 and a low of $19.96.

What is the 52 week high and 52 week low for Catalyst Pharmaceuticals share?

Catalyst Pharmaceuticals share touched a 52 week high of $26.58 and a 52 week low of $19.00. Catalyst Pharmaceuticals stock price today i.e. August 28, 2025 at 12:36 am IST is trending at $20.12, lower by 24.3% versus the 52 week high.

How to invest in Catalyst Pharmaceuticals Stock (CPRX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Catalyst Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Catalyst Pharmaceuticals Shares that will get you 0.0746 shares as per Catalyst Pharmaceuticals share price of $20.12 per share as on August 28, 2025 at 12:36 am IST.

What is the minimum amount required to buy Catalyst Pharmaceuticals Stock (CPRX) from India?

Indian investors can start investing in Catalyst Pharmaceuticals (CPRX) shares with as little as ₹87.86 or $1 (as of August 27, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹878.60 in Catalyst Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on August 27, 2025). Based on Catalyst Pharmaceuticals share’s latest price of $20.12 as on August 28, 2025 at 12:36 am IST, you will get 0.4970 shares of Catalyst Pharmaceuticals. Learn more about fractional shares .

What are the returns that Catalyst Pharmaceuticals has given to Indian investors in the last 5 years?

Catalyst Pharmaceuticals stock has given 500.45% share price returns and 18.89% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?